利妥昔单抗联合氯沙坦钾治疗慢性肾小球肾炎的效果  

Effect of Rituximab Combined with Losartan Potassium in the Treatment of Chronic Glomerulonephritis

作　　者：滕绍桦 Teng Shaohua(Department of Nephrology,Beijing Jishuitan Hospital Guizhou Hospital,Guiyang 550007,Guizhou Province,China)

机构地区：[1]北京积水潭医院贵州医院肾内科,贵州贵阳550007

出　　处：《中外医药研究》2024年第20期60-62,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:探究利妥昔单抗联合氯沙坦钾治疗慢性肾小球肾炎的效果。方法:选取2022年1月—2023年9月北京积水潭医院贵州医院收治的慢性肾小球肾炎患者120例为研究对象,随机分为对照组和观察组,各60例。对照组采用氯沙坦钾治疗,观察组采用利妥昔单抗联合氯沙坦钾治疗。比较两组临床疗效、症状消失时间、肾功能指标、炎性因子水平。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P=0.004);观察组恶心呕吐、水肿、疲乏消失时间均短于对照组,差异有统计学意义(P<0.001);治疗后,两组血肌酐、血尿素氮、24 h尿蛋白定量、尿红细胞、尿酸水平低于治疗前,观察组低于对照组,差异有统计学意义(P<0.05);治疗后,观察组白细胞计数、白细胞介素-6、肿瘤坏死因子-α、C反应蛋白水平均低于对照组,差异有统计学意义(P<0.05)。结论:利妥昔单抗联合氯沙坦钾治疗慢性肾小球肾炎的效果较好,有助于改善临床症状及肾功能,降低炎性因子水平。Objective:To explore the effect of rituximab combined with losartan potassium on chronic glomerulonephritis.Methods:A total of one hundred and twenty patients with chronic glomerulonephritis admitted to Beijing Jishuitan Hospital Guizhou Hospital from January 2022 to September 2023 were selected as the study objects,and were randomly divided into control group and observation group,with sixty cases in each group.The control group was treated with losartan potassium,and the observation group was treated with rituximab combined with losartan potassium.The clinical efficacy,symptom disappearance time,renal function index and inflammatory factor level were compared between the two groups.Results:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P=0.004);the time of nausea,vomiting,edema and fatigue in the observation group was shorter than that in the control group,the difference was statistically significant(P<0.001);after treatment,the levels of serum creatinine,blood urea nitrogen,24 h urinary protein,urinary red blood cells and uric acid in both groups were lower than before treatment,and the observation group was lower than control group,the difference was statistically significant(P<0.05);after treatment,the leukocyte count,interleukin-6,tumor necrosis factor-αand C-reactive protein levels in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).Conclusion:Rituximab combined with losartan potassium has a good effect on chronic glomerulonephritis,which is helpful to improve clinical symptoms and renal function,and reduce the level of inflammatory factors.

关 键 词：利妥昔单抗 氯沙坦钾 慢性肾小球肾炎 肾功能 

分 类 号：R692.31[医药卫生—泌尿科学]